Success Stories: No-RFE NIW Approval Achieved for Pharmaceutical Biotechnology Assistant Professor with NAILG’s Expert Filing

Client’s Testimonial:

“I want to take a moment to express my appreciation for your assistance in handling my immigration petition. Your expertise and guidance throughout the process have been invaluable, and I truly appreciate the time and effort you put into my case.”

On April 9^th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for an Assistant Professor in the Field of Pharmaceutical Biotechnology (Approval Notice).

General Field: Pharmaceutical Biotechnology

Position at the Time of Case Filing: Assistant Professor

Country of Origin: India

State of Residence at the Time of Filing: New Jersey

Approval Notice Date: April 9^th, 2025

Processing Time: 1 month, 19 days (Premium Processing Requested)

Case Summary:

In the field of pharmaceutical biotechnology, the client stands out for her pioneering work on the biological mechanisms behind some of the most urgent and widespread health challenges in the United States: osteoporosis, obesity, and Alzheimer’s disease. Her proposed endeavor centers on investigating how Follicle-Stimulating Hormone (FSH) influences disease-related pathways and identifying therapeutic targets to guide the development of innovative treatments.

To pursue her long-term research goals in the United States, our client retained the North America Immigration Law Group (NAILG) to prepare and file a National Interest Waiver (NIW) petition. The legal team carefully demonstrated how her research not only meets the standards of scientific merit but also addresses national healthcare priorities with broad public health implications.

The petition emphasized the national importance of her work in translational research and pointed to her history of federal funding as a clear endorsement of its impact. Our client’s research has been supported by the National Institute on Aging (NIA), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the National Institute of General Medical Sciences (NIGMS), all agencies deeply invested in the treatment and prevention of chronic diseases affecting millions of Americans.

To substantiate her standing in the field, NAILG presented the following evidence:

9 peer-reviewed journal articles, including 2 first-authored, 5 scientific abstracts (1 first-authored), 1 preprint, 1 first-authored book chapter, and 1 technical report,
20+ peer reviews completed for scientific journals,
Editorial leadership as a guest editor for a special issue,
And 110 citations, indicating growing scholarly recognition.

“In conclusion, [client]’s leadership in pharmaceutical biotechnology is clearly demonstrated by her robust publication portfolio and cutting-edge developments on unraveling protein aggregation mechanisms in neurodegenerative disorders. There is thus no doubt that [client] shall continue to produce additional valuable research, both driving progress in the field and bringing immense benefits to national and international concerns.”

NAILG’s petition strategy positioned her work not only as scientifically innovative, but as essential to mitigating the rising burden of age-related and metabolic diseases in the U.S. By highlighting her contributions to the understanding of protein aggregation and her pursuit of targeted therapies, the petition demonstrated the direct relevance of her research to national public health goals.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.